Key Highlights
- SLS shares rose 165.60% in today's session to $19.84 from a prior close of $7.47.
- REGAL met its primary endpoint with a hazard ratio of 0.59 (p=0.035).
- Median overall survival was 24.0 months versus 14.7 months for best available treatment.
- SELLAS plans a BLA submission in the first half of 2027.
SELLAS Life Sciences (NASDAQ:SLS) shares surged in today's session after the company announced positive topline results from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The stock was at $19.84, up 165.60% from the prior close of $7.47, on Volume of about 101 million shares against an average of about 7 million. The shares opened at $24.00, and the 52-week range runs from $1.39 to $24.89.
SELLAS is a New York-based, late-stage clinical biopharmaceutical company developing therapies for a broad range of cancer indications. GPS is a WT1-targeting peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center. The company is also developing SLS009 (tambiciclib), a CDK9 inhibitor.
What Did the REGAL Trial Show?
REGAL met its primary endpoint of overall survival. GPS showed a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a p-value of 0.035, and median overall survival of 24.0 months versus 14.7 months for best available treatment. The company reported no new safety signals.
The global, randomized, open-label trial enrolled 126 patients, randomized 1:1 to GPS or best available treatment. Patients had achieved a second or later complete remission and were ineligible for, or unable to undergo, allogeneic stem cell transplantation. The analysis followed the pre-specified occurrence of 80 events.
What Happens Next With the FDA?
SELLAS plans to meet with the FDA to discuss an accelerated filing path and is preparing a Biologics License Application for GPS in the first half of 2027. Analysis of secondary endpoints is underway, with detailed results to be presented at an upcoming major medical conference.
Which Details Are Investors Watching?
Investors are focused on the FDA dialogue, the secondary-endpoint data and the Margin behind the p-value. Maxim's $30 price target is the only recent Buy rating cited. SLS009 Phase 2 data are due this quarter, and the company ended September with $134.7 million in cash.
The FDA Meeting and Full Data Set Set the Next Checkpoints
The FDA meeting, the detailed secondary-endpoint results and the SLS009 Phase 2 data are the next points to watch. The company noted that final results may differ from the topline data and that the FDA may not agree with its analyses.


_11_17_2026_19_45_07_327614.jpg)
_11_17_2026_18_59_44_560836.jpg)


Please wait processing your request...